+91-8668442535

Polymyositis Treatment Market By Type Of Drug Class (Immunosuppressant, Alkylating Agent, Immunoglobulin, Monoclonal Antibodies, Corticosteroids) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

The polymyositis treatment market is projected to grow at a CAGR of 5.9% during the forecast period from 2019 to 2027. Polymyositis is a rare connective tissue disease that causes muscle inflammation, leading to muscle weakness. According to prevalence studies, globally, the incidence of polymyositis is around 1 to 5 per 100,000 individuals, and the prevalence is approximately 5 to 22 per 100,000 individuals. Thus, high awareness related to polymyositis diagnosis and treatment, a strong drug pipeline, and a rising geriatric population is expected to assist the growth of the polymyositis treatment market in the near future.

Market Synopsis

Abatacept and octagram are expected to grow significantly throughout the forecast period because they are highly efficient compared to currently available drugs.

The pipeline for polymyositis treatment is strong and comprises potential molecules that will drive the growth of the overall market in the near future. Abatacept and octagram (10%) are two of the most potent drugs under phase III clinical trials and are anticipated to perform better than the drugs currently on the market. Abatacept is a human fusion protein of CTLA-4 and the Fc portion of human IgG1 that inhibits the co-stimulation of T cells. Octagam is an immune globulin intravenous (human), and currently, octagon 5% liquid is approved for the treatment of primary humoral immunodeficiency (PI) and other severe combined immunodeficiencies. However, its application for polymyositis treatment is under trial, but results in Phase II trials have been satisfactory in terms of immune system recovery.

Asia Pacific is the fastest growing market due to the rising geriatric population in Japan and increasing awareness related to polymyositis treatment and diagnosis.

During the forecast period from 2019 to 2027, Asia Pacific was identified as the fastest-growing polymyositis treatment market, mainly due to increasing awareness among medical practitioners related to polymyositis and an increasing geriatric population in Japan, China, and South Korea. According to studies, in 2010, the prevalence of polymyositis was estimated to be 13.2 cases per 100,000 individuals in Japan. Japan was identified as the largest polymyositis treatment market due to the rising geriatric population, increasing demand for target-specific drugs, and high awareness related to polymyositis treatment and diagnosis.

Historical and Forecast Period

The polymyositis treatment market was analyzed considering current market trends for the base year of2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report covers the in-depth analysis of the polymyositis treatment market, covering market trends, strategies, and product lifecycles analyzed based on detailed qualitative and quantitative data collected through primary and secondary research. Through primary interviews, industry stakeholders have studied and understood market dynamics such as opportunities, drivers, and challenges further segmented by region and respective countries. This report also includes a comprehensive study of multiple segments of global polymyositis treatment, such as the type of drug class and geography.

Pipeline analysis includes information related to molecules that are under clinical trial and expecting approval in the near future. The report also covers an understanding of the competitive landscape of the major companies present in the polymyositis treatment market, which covers data points such as current and future business strategies, financial data, and the product portfolios of respective companies.

The major companies present in the market were studied based on recent market updates, product portfolios, financial data, and major strategies. This report also covers attractive investment propositions analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key players operating in the overall report are Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG, Genentech, Inc., among others.

Key questions are answered in this report.

  • Which drug class is in high demand to treat polymyositis, and why?
  • What are the present market strategies & policies studied & applied by key market players & the competitive landscape of the global polymyositis treatment market?
  • Which are the crucial and imminent geographical markets (regions and countries) in the polymyositis treatment market, and why?
  • Which is the largest and fastest-growing region and country globally?
  • What will be the expected sales of drugs under development?

Frequently Asked Question:

The market for Polymyositis Treatment Market is expected to reach USD$ XX in 2027.

The Polymyositis Treatment Market is expected to see significant CAGR growth over the coming years, at 5.9%.

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG,are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59742
Report Format:   PDF
Pages:   120
Rating:    4.2 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support